Medicus Pharma (MDCX) Return on Equity (2024 - 2025)
Medicus Pharma (MDCX) reported Return on Equity of 0.39% for Q4 2025, up 42.0% on a YoY basis from 0.27% in Q4 2024, and up 407.6% quarter-over-quarter from 0.13% in Q3 2025.
Medicus Pharma (MDCX) Return on Equity (2024 - 2025) Analysis & Trends
Medicus Pharma has reported Return on Equity for 2 years, with the latest figure at 0.39% in Q4 2025.
- For the quarter ending Q4 2025, Return on Equity rose 42.0% year-over-year to 0.39%; the trailing twelve-month figure through Dec 2025 stood at 0.39% (up 42.0% YoY), and the FY2025 full-year result was 0.22%, down 17.0% from the prior year.
- Return on Equity for Q4 2025 stood at 0.39%, up from 0.13% in the prior quarter.
- The five-year high for Return on Equity was 0.39% in Q4 2025, with the low at 0.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 0.01% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 0.00% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -0.01% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 0.00% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 0.01% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 0.00% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.00% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 0.00% |
| 10 | Medicus Pharma | 6.05 Mn | 6.15 Mn | - | 0.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.39% |
| Sep 30, 2025 | -0.13% |
| Jun 30, 2025 | -0.06% |
| Mar 31, 2025 | -0.06% |
| Dec 31, 2024 | -0.03% |
| Sep 30, 2024 | -0.01% |